ASPECT BIOSYSTEMS TO PRESENT NEW DATA ON BIOPRINTED LIVER TISSUES AT AASLD LIVER MEETING 2021

Presentation will highlight the development of functional 3D bioprinted co-cultured human hepatocyte spheroids for use as a liver tissue therapeutic 

Vancouver, BC, Canada, November 3, 2021 - Aspect Biosystems, a biotechnology company pioneering the development of bioprinted cell therapies as medicines of the future, will present new data on its bioprinted liver tissues at the The Liver Meeting 2021, hosted by the American Association for the Study of Liver Diseases (AASLD), held virtually from November 12-15, 2021. This data highlights that the bioprinted liver tissues maintain viability and function for over 28 days in vivo.